Accenture and the Bristol-Myers Squibb Company have together launched the pharmaceutical industry’s first ‘pharmacovigilance’ center, in Chennai, India, to monitor safety of data collected on medicines. Pharmacovigilance entails the capture, assessment and reporting of potential side effects on medicines. The new center will undertake the processing and coding of adverse event data and the generation of regulatory periodic and aggregate reports on safety as well as physician medical review of adverse events. The opening of the center, marks the first time a collaboration for ‘end-to-end’ safety case processing has been established.The center promises seamless handling of data and reports between Accenture and Bristol-Myers Squibb while not compromising patient safety. The pharmacovigilance center, to be operated by more than 140 Accenture employees, is part of Accenture’s Life Sciences Centers of Excellence in Bangalore and Chennai that Bristol-Myers Squibb already utilizes.